Ipsen (FR:IPN) has released an update.
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Ipsen has expanded its agreement with Exelixis, leveraging promising results from the CABINET Phase III trial to potentially market Cabometyx® for advanced neuroendocrine tumors in territories excluding the U.S. and Japan. The trial showed a significant improvement in progression-free survival for patients with advanced pancreatic and extra-pancreatic neuroendocrine tumors. Ipsen is now in discussions with EU regulatory authorities to pursue marketing authorizations based on these clinical findings.
For further insights into FR:IPN stock, check out TipRanks’ Stock Analysis page.